PT-141 (Bremelanotide)
Melanocortin Receptor Agonist — FDA-Approved Nasal Spray for HSDD; Grey Market Injection
Sexual Health
Version 2025-04 · Last Reviewed April 1, 2025
About this review (v2025-04, last reviewed April 1, 2025): This review was compiled from published preclinical and clinical research, FDA regulatory documents, and compounding pharmacy guidance. No peptide vendor or manufacturer reviewed or approved this content. Read our full methodology
Educational content only. This page reflects published research and does not constitute medical advice. Peptides are not FDA-approved drugs (with limited exceptions noted). Consult a licensed healthcare provider before use. Dosing is intentionally omitted — it is determined by your provider based on individual labs and goals.
What it is
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist derived from Melanotan II. Unlike phosphodiesterase inhibitors (Viagra, Cialis) which work peripherally by increasing blood flow to genitalia, PT-141 works centrally — it crosses the blood-brain barrier and acts on melanocortin receptors in the hypothalamus and limbic system to promote sexual arousal. It was FDA-approved in 2019 as Vyleesi (intranasal) for premenopausal women with HSDD.
Regulatory status
PT-141 (bremelanotide) is FDA-approved as Vyleesi (intranasal spray, 1.75mg) for hypoactive sexual desire disorder (HSDD) in premenopausal women. The grey market injectable form is not FDA-approved. Prescribers may prescribe Vyleesi for on-label use. Off-label injectable compounding is a separate unregulated space.
Mechanism of Action
PT-141 selectively activates melanocortin receptors 3 and 4 (MC3R and MC4R) in the central nervous system, particularly in areas governing sexual motivation and arousal (hypothalamus, nucleus accumbens). This central mechanism distinguishes it from vascular sexual dysfunction drugs. It does not require sexual stimulation in the same way PDE5 inhibitors do. A notable side effect is transient blood pressure elevation, which is why it carries FDA warnings and is contraindicated in cardiovascular disease.
What Research Has Explored
These are areas of published research — not personal recommendations.
Hypoactive sexual desire disorder (HSDD) in women
PT-141 (bremelanotide) is FDA-approved for HSDD in premenopausal women based on Phase III trials showing significant improvement in desire scores and reduction in distress vs placebo.
Context: This is the only FDA-approved indication. The approval specifically covers the nasal spray form (Vyleesi), not injectable forms.
Sexual dysfunction in men
Earlier Phase II studies showed PT-141 improved erectile response in men with PDE5i-refractory erectile dysfunction, including men who did not respond to Viagra or Cialis.
Context: No FDA approval exists for male sexual dysfunction. Clinical development for male use was suspended. Men using grey market injectable PT-141 are outside any approved or supervised framework.
Stability & Delivery Form — Why This Matters
Most peptides are fragile molecules destroyed by stomach acid and digestive enzymes. Delivery form determines whether the peptide survives to reach your bloodstream.
Capsule / Pill Warning
PT-141 (Bremelanotide) in capsule or pill form has no meaningful systemic bioavailability. Stomach acid and digestive enzymes destroy the peptide bonds before absorption. If a product is sold as a capsule claiming the systemic effects of the injectable form, it cannot deliver those effects. This is a red flag about the vendor's credibility.
FDA-approved intranasal spray (Vyleesi, 1.75mg)
The only FDA-approved and commercially available legitimate form. Administered as a nasal spray 45 minutes before anticipated sexual activity. Vyleesi is available by prescription at retail pharmacies.
Subcutaneous injection (grey market)
Injectable PT-141 has bioavailability but exists only as grey market or compounded peptide. No FDA-approved injectable form exists. Blood pressure spikes are reported to be more pronounced with injection than with nasal spray.
Oral capsule
PT-141 is a peptide destroyed in the GI tract. Oral capsules claiming systemic PT-141 effects have no bioavailability and are ineffective.
Reconstitution & Storage
If using grey market injectable (not recommended): Reconstitute with bacteriostatic water. Refrigerate at 2–8°C. Standard lyophilized peptide storage applies. Note: the FDA-approved nasal spray (Vyleesi) comes pre-filled — no reconstitution needed.
Dosing is intentionally not listed here. It is determined by your provider based on individual labs, goals, and clinical context.
Frequently Asked Questions About PT-141 (Bremelanotide)
- What is PT-141 (Bremelanotide)?
- PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist derived from Melanotan II. Unlike phosphodiesterase inhibitors (Viagra, Cialis) which work peripherally by increasing blood flow to genitalia, PT-141 works centrally — it crosses the blood-brain barrier and acts on melanocortin receptors in the hypothalamus and limbic system to promote sexual arousal. It was FDA-approved in 2019 as Vyleesi (intranasal) for premenopausal women with HSDD.
- What is PT-141 (Bremelanotide) used for in research?
- PT-141 (bremelanotide) is the only peptide in this directory with FDA approval — as an intranasal spray (Vyleesi) for HSDD in premenopausal women; all other forms and uses exist outside approved frameworks and require careful risk/benefit evaluation. Research areas include: Hypoactive sexual desire disorder (HSDD) in women, Sexual dysfunction in men.
- Is PT-141 (Bremelanotide) FDA approved?
- PT-141 (bremelanotide) is FDA-approved as Vyleesi (intranasal spray, 1.75mg) for hypoactive sexual desire disorder (HSDD) in premenopausal women. The grey market injectable form is not FDA-approved. Prescribers may prescribe Vyleesi for on-label use. Off-label injectable compounding is a separate unregulated space.
- How is PT-141 (Bremelanotide) administered?
- FDA-approved nasal spray (Vyleesi) or grey market subcutaneous injection
- What are the safety risks of sourcing PT-141 (Bremelanotide)?
- Key risks when sourcing PT-141 (Bremelanotide) from grey-market or research suppliers include: Blood pressure elevation is a documented pharmacological effect of PT-141. Without monitoring, a hypertensive individual using grey market injectable PT-141 faces real cardiovascular risk. The FDA-approved nasal spray includes blood pressure monitoring guidance; grey market use does not.; Nausea is the most common side effect — occurs in up to 40% of users in clinical trials. Without proper dosing guidance, grey market users may receive higher doses than studied.; Flushing and hyperpigmentation (darkening of skin, particularly face, gums, and breasts) are reported with repeated use, particularly with the older Melanotan II precursor.; Standard contamination and adulteration risks of all grey market injectables apply..
- Who should avoid or be cautious about PT-141 (Bremelanotide)?
- PT-141 (Bremelanotide) should be used with caution or avoided by: Cardiovascular disease, hypertension, or history of stroke — PT-141 raises blood pressure. FDA labeling states it should not be used in these populations.; Postmenopausal women — not studied in this population; Vyleesi is approved only for premenopausal HSDD.; Men — no FDA approval; male use is off-label and outside studied protocols.; Dark-skinned individuals using repeatedly — hyperpigmentation risk with melanocortin receptor agonism..
Stay informed — get updates when we add new medications
We add new medications and supplements regularly. No spam, ever.
No spam. Unsubscribe anytime.